Latest close: a new 52-week highSep 8, 2026what changed →6/10Strongest Momentum, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
Price
$41.47+251%1Y
1M+18%1Y+251%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageValue64
Quality26
Momentum92
Growth7
What they do
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter.
In the company’s own words · 10-K filed May 20, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$24.47B
1Y Return+251%
5Y Return+317%
Roivant Sciences Ltd. (ROIV) reported revenue of $2.5M in Q4 2025 (quarter ended Mar 31, 2026), down 67% from the same quarter a year earlier. That came with net income of $303M (12024% of revenue). For the full year FY2025, revenue was $8.3M (−72% year on year) and net income −$300M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
Ranks #59 of 143 by Smart Score